Date receipt dossier
Company / Sponsor
Schering N.V./S.A.
Phase
IIb/III
Treated organism
Humans
Indication category
Cardiovascular therapy
Disease
Chronic angina pectoris
Therapeutic approach
Gene therapy
Genetic modification
human FGF-4
Method of transfer of nucleic acid of interest
Human Adenovirus serotype 5
Administered biological material
Recombinant Adenovirus D (E1A, E1B)
Route of administration
Intracoronary
Locations in Belgium
Universitair Ziekenhuis Gasthuisberg, Leuven - O.-L.-Vrouwziekenhuis, Aalst
Type of procedure
Contained use only
Current status
Authorized
Pharmaceutical study code
305602